MiNK Q1 net loss narrows to $3.8M; $5.8M PIPE to fund MiNK-215 IND in 2025

MiNK Therapeutics, Inc.

2024-Q1 EPS reported -$0.11

Net loss of $3.8M ($0.11 per share) vs $5.7M ($0.17) YoY; cash used in ops $2.5M.
Quarter-end cash $5.8M; closed $5.8M PIPE at 25% premium with new investor.
Phase 2 trial of agenT-797 in gastroesophageal cancers actively enrolling; initial results expected H2 2024.
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models (AACR data).
Upcoming ATS presentation (May 21) on agenT-797 in severe respiratory distress in a renal transplant patient.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.

Period: for the first quarter 2024
Net income: $3.8 million, or $0.11 per share
EPS: $0.11 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002826

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.